Descriptive characteristics of patients enrolled in the John Ruedy Immunodeficiency
| No. (%) of patients*† | p value | ||
|---|---|---|---|
| Alive at end of study period n = 1830 | Died during study period n = 271 | ||
| Characteristic | |||
| Male sex | 1596 (87.2) | 228 (84.1) | 0.2 |
| Risk factor(s) for HIV infection | |||
| Injection drug use only | 123 (6.7) | 63 (23.2) | |
| MSM only | 705 (38.5) | 51 (18.8) | |
| Injection drug use + MSM | 161 (8.8) | 34 (12.5) | |
| Other‡ | 696 (38.0) | 101 (37.3) | |
| Unknown | 145 (7.9) | 22 (8.1) | < 0.001 |
| Age at first clinic visit, yr, median (Q1–Q3) | 41 (34–49) | 46 (40–53) | < 0.001 |
| Year of clinic enrolment | |||
| 2004–2005 | 421 (23.0) | 124 (45.8) | |
| 2006–2009 | 652 (35.6) | 107 (39.5) | |
| 2010–2014 | 757 (41.4) | 40 (14.8) | < 0.001 |
| Baseline CD4 count, cells × 106/L§ | |||
| < 50 | 81 (4.4) | 48 (17.7) | |
| 50–199 | 287 (15.7) | 71 (26.2) | |
| 200–349 | 397 (21.7) | 59 (21.8) | |
| ≥ 350 | 1055 (57.6) | 93 (34.3) | < 0.001 |
| Baseline plasma viral load, copies/mL§ | |||
| < 50 | 722 (39.4) | 83 (30.6) | |
| 50–99 999 | 835 (45.6) | 127 (46.9) | |
| ≥ 100 000 | 265 (14.5) | 61 (22.5) | < 0.001 |
| Hepatitis virus infection¶ | |||
| Chronic hepatitis B | 103 (5.6) | 10 (3.7) | 0.3 |
| Chronic hepatitis C | 346 (18.9) | 64 (23.6) | < 0.001 |
| ART (ever during study period) | 1671 (91.3) | 243 (89.7) | 0.4 |
| Year of ART initiation | |||
| Before 2000 | 371 (20.3) | 108 (39.8) | |
| 2000–2006 | 406 (22.2) | 91 (33.6) | |
| 2007–2015 | 974 (53.2) | 57 (21.0) | |
| Unknown | 79 (4.3) | 15 (5.5) | < 0.001 |
| Latest CD4 count, cells × 106/L** | |||
| < 50 | 15 (0.9) | 41 (16.0) | |
| 50–199 | 104 (5.9) | 75 (29.3) | |
| 200–349 | 232 (13.3) | 50 (19.5) | |
| ≥ 350 | 1398 (79.9) | 90 (35.2) | < 0.001 |
| Latest plasma viral load, copies/mL** | |||
| < 50 | 1495 (84.2) | 143 (55.9) | |
| 50–99 999 | 247 (13.9) | 80 (31.2) | |
| ≥ 100 000 | 33 (1.9) | 33 (12.9) | < 0.001 |
| Visit constancy (first yr), % | |||
| < 75 | 554 (30.8) | 92 (48.4) | |
| ≥ 75 | 1242 (69.2) | 98 (51.6) | < 0.001 |
| ART adherence (≥ 95%; first yr)†† | 1085 (59.3) | 81 (29.9) | < 0.001 |
Note: ART = antiretroviral therapy, MSM = men who have sex with men.
↵* Except where noted otherwise.
↵† Numbers do not total 2101 for some variables owing to incomplete data.
↵‡ Includes risk of heterosexual transmission alone or in combination with MSM and/or injection drug use, as well as accidental exposure.
↵§ Most recent within 6 months of first clinic visit.
↵¶ Chronic hepatitis B: positive result of testing for hepatitis B surface antigen or hepatitis B virus DNA for 6 months or more; chronic hepatitis C: positive results of testing for hepatitis C virus antibody and RNA, or for hepatitis C virus genotypes 1a–4.
↵** Most recent before death or study censor date.
↵†† Based on pharmacy refill frequency.